Developing prototype injectability and developability testing system based on microfluidic quartz resonators
开发基于微流控石英谐振器的原型可注射性和可开发性测试系统
基本信息
- 批准号:10384221
- 负责人:
- 金额:$ 59.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-08 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcousticsAddressAntibody TherapyBehaviorBiological ProductsBlood capillariesClinicComputer softwareDataDevelopmentDevicesDimensionsDoseDropsEnsureFDA approvedFailureFormulationHealth Care CostsHealth care facilityHeightHomeIndustryInjectableInjectionsIntravenous infusion proceduresInvestmentsLiquid substanceMeasurementMeasuresMicrofluidicsModulusMonoclonal AntibodiesMotionPatient PreferencesPatientsPharmaceutical PreparationsPhasePositioning AttributeProblem SolvingProcessProteinsQuartzRheologyRiskSamplingSideSmall Business Innovation Research GrantSubcutaneous InjectionsSurfaceSystemTechniquesTechnologyTestingTherapeuticThickThinnessTimeViscositybasecandidate selectioncommercializationcostdata acquisitiondrug developmentimprovedinstrumentmanufacturabilitymilliliterphase 1 studypreclinical developmentprotein protein interactionprototyperesearch and developmentscale upsensorstem
项目摘要
The objective of this SBIR Phase II proposal is to carry QATCH’s nanovisQ™ technology, which is a wide-
shear-rate range and low volume viscometer for determining developability and injectability of biopharmaceutical
formulations, from proof-of-concept to deployable, and reliable prototypes. This objective is motivated by the
needs of the growing protein-based biopharmaceutical therapeutics industry (with global market size over $100
billion). Protein-based therapeutics are administered as high concentration formulations due to the volume
constraints of subcutaneous injections. However, increased protein-protein interactions at these high
concentrations can cause injectability and manufacturability issues, which cannot be determined at early stages
of drug development due to the high sample volume requirements of conventional rheology techniques. By
developing a wide shear rate range, low volume viscometer, protein molecules can be optimized for
injectability/manufacturability and candidates with better developability can be selected for scaling-up. This
proposal is significant because the proposed device can assess injectability of protein formulations earlier in
drug development than existing technology and consequently reduce the time and cost of R&D spent in
developing new, injectable protein-based therapeutics considerably. In SBIR Phase I studies, QATCH has
successfully extended the shear-rate range of viscosity measurements of the nanovisQ™ for proper
characterization of the high concentration protein solutions. As a result, the nanovisQ™ is now positioned to be
a good fit for viscosity measurements of high concentration protein formulations. In SBIR Phase II QATCH is
proposing to 1) develop a sacrificial poly-Si based fabrication process to build microfluidics on quartz wafers,
2) develop a prototype control and data acquisition module for nanovisQ™ sensors. Developing deployable and
reliable nanovisQ™ sensors and instruments will be a key step in commercialization of this technology.
这项SBIR第二阶段提案的目标是采用QATCH的nanovisQ™技术,该技术是一项广泛的
用于测定生物药物可显影性和可注射性的剪切速率范围和小体积粘度计
从概念验证到可部署和可靠的原型。这一目标的动机是,
不断增长的基于蛋白质的生物制药治疗行业(全球市场规模超过100美元)的需求
十亿)。基于蛋白质的治疗剂由于体积而作为高浓度制剂施用。
皮下注射的限制。然而,在这些高水平下增加的蛋白质-蛋白质相互作用
浓度可能导致注射性和可制造性问题,这些问题在早期阶段无法确定
由于传统流变学技术对样品体积的要求很高,因此,这一技术在药物开发中的应用非常有限。通过
开发宽剪切速率范围、低体积粘度计,可以优化蛋白质分子,
可注射性/可制造性和具有更好可显影性的候选物可被选择用于按比例放大。这
该建议是重要的,因为所提出的装置可以在更早的时间评估蛋白质制剂的可注射性。
药物开发比现有技术,从而减少研发的时间和成本,
开发新的,可注射的基于蛋白质的治疗方法。在SBIR I期研究中,QATCH
成功扩展了nanovisQ™粘度测量的剪切速率范围,
高浓度蛋白质溶液的表征。因此,nanovisQ™现在被定位为
非常适合高浓度蛋白质制剂的粘度测量。在SBIR第二阶段,QATCH是
提出1)开发基于牺牲多晶硅的制造工艺以在石英晶片上构建微流体,
2)为nanovisQ™传感器开发原型控制和数据采集模块。开发可部署和
可靠的nanovisQ™传感器和仪器将是该技术商业化的关键一步。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zehra Parlak其他文献
Zehra Parlak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zehra Parlak', 18)}}的其他基金
High-throughput injectability screening of high concentration protein formulations by microfluidic quartz resonators
通过微流控石英谐振器对高浓度蛋白质制剂进行高通量可注射性筛选
- 批准号:
10760592 - 财政年份:2023
- 资助金额:
$ 59.87万 - 项目类别:
Developing prototype injectability and developability testing system based on microfluidic quartz resonators
开发基于微流控石英谐振器的原型可注射性和可开发性测试系统
- 批准号:
10569024 - 财政年份:2022
- 资助金额:
$ 59.87万 - 项目类别:
Injectability analysis of high concentration protein formulations by extending shear-rate range in microfluidic quartz viscometers
通过扩展微流控石英粘度计的剪切速率范围来分析高浓度蛋白质制剂的可注射性
- 批准号:
10080997 - 财政年份:2020
- 资助金额:
$ 59.87万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 59.87万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 59.87万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 59.87万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 59.87万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 59.87万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 59.87万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 59.87万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 59.87万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 59.87万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 59.87万 - 项目类别:
Research Grant